Introductory Paragraph {#S1}
======================

Soft tissue sarcomas, which encompass approximately 10,700 diagnoses and 3800 deaths per year in the US[@R1], exhibit remarkable histologic diversity, with more than 50 recognized subtypes[@R2]. However, knowledge of their genomic alterations is limited. We describe an integrative analysis of DNA sequence, copy number, and mRNA expression in 207 samples encompassing seven major subtypes. Frequently mutated genes included *TP53* (17% of pleomorphic liposarcomas), *NF1* (10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas), and *PIK3CA* (18% of myxoid/round-cell liposarcomas). *PIK3CA* mutations in myxoid/round-cell liposarcomas were associated with AKT activation and poor clinical outcomes. In myxofibrosarcomas and pleomorphic liposarcomas, we found both point mutations and genomic deletions affecting the tumor suppressor *NF1*. Finally, we found that shRNA-based knockdown of several genes amplified in dedifferentiated liposarcoma, including *CDK4* and *YEATS4*, decreased cell proliferation. Our study yields a detailed map of molecular alterations across diverse sarcoma subtypes and provides potential subtype-specific targets for therapy.

Current knowledge of the key genomic aberrations in soft tissue sarcoma is limited to the most recurrent alterations or translocations. Subtypes with simple, near-diploid karyotypes bear few chromosomal rearrangements but have pathognomonic alterations: translocations in myxoid/round-cell liposarcoma (MRC) \[t(12;16)(q13;p11), t(12;22)(q13;q12)\] and synovial sarcomas (SS) \[t(X;18)(p11;q11)\]; activating mutations in *KIT* or *PDGFRA* in gastrointestinal stromal tumors (GIST)[@R3],[@R4]. The discovery of the latter mutations led to the clinical deployment of imatinib for the treatment of GIST[@R5], providing a model for genotype-directed therapies in molecularly defined sarcoma subtypes. Conversely, sarcomas with complex karyotypes, including dedifferentiated and pleomorphic liposarcoma, leiomyosarcoma, and myxofibrosarcoma, have no known characteristic mutations or fusion genes, although abnormalities are frequently observed in the Rb, p53, and specific growth-factor signaling pathways[@R6].

Recent large-scale analyses[@R7]--[@R10] have established a standard for cancer genome studies, but soft tissue sarcomas have not yet been a focus of this type of effort. Given the urgent need for new treatments for the \~4000 patients who die each year in the US of soft tissue sarcoma[@R1], we sought to identify novel genomic alterations that could serve as therapeutic targets. Here, we describe complementary genome and functional genetic analyses of seven subtypes of high-grade soft tissue sarcoma ([Table 1](#T1){ref-type="table"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}) to discover subtype-specific events. Several of our findings, detailed below, could have nearly immediate therapeutic implications.

To study the genomic alterations in sarcomas, we initially analyzed 47 tumor/normal DNA pairs encompassing six soft tissue sarcoma subtypes by sequencing 722 protein-coding and microRNA genes, followed by verifying discovered mutations with mass spectrometry-based genotyping (see Methods, [Supplementary Figure 1A, and Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The results revealed 28 somatic non-synonymous coding point mutations and 9 somatic insertions/deletions (indels) involving 21 genes in total ([Table 2](#T2){ref-type="table"} and [Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}). No mutations were detected in microRNAs genes. We extended the analysis to an additional 160 tumors, where we genotyped each of the mutations found above and re-sequenced exons of *NF1* and *ERBB4* in pleomorphic liposarcoma and myxofibrosarcoma, *PIK3CA* and *KIT* in myxoid/round cell liposarcoma, and *CDH1* in dedifferentiated liposarcoma; this revealed nine additional mutations ([Table 2](#T2){ref-type="table"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

*KIT* was frequently mutated in GISTs and unexpectedly, in one myxoid/round cell liposarcoma sample ([Supplementary Note](#SD1){ref-type="supplementary-material"}). The next most frequently mutated genes observed within specific sarcoma subtypes were *PIK3CA*, in 18% of myxoid/round cell liposarcomas, *TP53* in 17% of pleomorphic liposarcomas (interestingly, the only subtype in which mutations of this gene were found), and *NF1* in 10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Additional genes, including protein and lipid kinases, as well as known or candidate tumor suppressor genes, were found mutated in just one sample for each sarcoma subtype ([Table 2](#T2){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}, and [Supplementary Note](#SD1){ref-type="supplementary-material"}). Further studies will be needed to establish the functional impact of these mutations in sarcoma.

Below, we focus on three major specific genomic findings with therapeutic implications: point mutation and deletion of *NF1* in a subset of soft tissue sarcomas, point mutation of *PIK3CA* in myxoid/round cell liposarcoma, and the complex pattern of amplification of chromosome 12q in dedifferentiated liposarcoma.

Integrated analysis of DNA copy number, expression, and mutation data uncovered diverse alterations of the Neurofibromatosis type 1 gene (*NF1*) in several sarcoma subtypes. While germline and somatic inactivation of *NF1* is associated with malignant peripheral nerve sheath tumors[@R11] and GISTs in Neurofibromatosis type 1 patients[@R12], no somatic *NF1* alterations have been reported in other sarcomas. We detected six point mutations and twelve genomic deletions encompassing the *NF1* locus, occurring in both myxofibrosarcoma and pleomorphic liposarcoma ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}, [2A--B](#F2){ref-type="fig"}; copy number analysis discussed further below). Two of the mutations, R304\* and Q369\*, were previously reported as germline mutations in patients with Neurofibromatosis type 1[@R13],[@R14], while the other four mutations (three missense and one nonsense) have not been previously reported. In some tumors, biallelic inactivation was evident, with heterozygous point mutations accompanied by deletion of the wild-type allele and correspondingly reduced gene expression compared to normal adipose tissue[@R15] in most cases ([Figure 2B](#F2){ref-type="fig"}). Together, these data indicate a diverse pattern of *NF1* aberrations in myxofibrosarcomas and pleomorphic liposarcomas. These results complement recent reports of *NF1* alterations in lung cancers and glioblastomas[@R7],[@R8].

*PIK3CA*, encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), had one of the highest somatic mutation frequencies among the genes in this analysis ([Table 2](#T2){ref-type="table"}). Nucleotide substitutions in *PIK3CA* were initially detected in 4 of 21 myxoid/round-cell liposarcomas (MRCs). We measured the frequency of point mutations in *PIK3CA* in this subtype by genotyping an independent cohort of 50 MRCs[@R16] for 13 common sites of *PIK3CA* mutation, including those discovered in our initial sequencing; mutations were detected in 9 additional patients (in total, 13 of 71). The mutations were clustered in two domains, the helical domain (E542K and E545K) and the kinase domain (H1047L and H1047R) ([Table 2](#T2){ref-type="table"}); both these domains are also mutated in epithelial tumors[@R17].

MRC patients whose tumors harbored mutations in *PIK3CA* had a shorter duration of disease--specific survival than did those with wildtype *PIK3CA* (p=0.036, log-rank test). Similar to observations in breast cancers[@R18], patients with helical-domain *PIK3CA* mutations had worse outcomes than those with kinase-domain mutations ([Figure 3A](#F3){ref-type="fig"}). However, this difference was not statistically significant given the small number of cases in our study.

As both helical- and kinase-domain *PIK3CA* mutants are believed to activate Akt, although through different mechanisms[@R19]--[@R21], we assessed Akt activation in MRC tumors harboring wildtype and mutated *PIK3CA*. Of note, only E545K helical-domain mutations were associated with increased Akt phosphorylation relative to wildtype, both at serine-473 and threonine-308 (TORC2 and PDK1 phosphorylation sites, respectively), and with increased phosphorylation of Akt substrates PRAS40 and S6 kinase ([Figure 3B](#F3){ref-type="fig"}). Surprisingly, tumors with H1047R kinase-domain mutations did not have similar increases in Akt phosphorylation or activation ([Figure 3B](#F3){ref-type="fig"}). However, H1047R-mutant tumors exhibited variably higher levels of PTEN, a negative regulator of PI3K activity, which may partly explain lower Akt activity. In addition, we detected a single MRC tumor with homozygous *PTEN* deletion and high Akt phosphorylation levels (data not shown). Further studies are needed to determine the relationship between activated PI3K signaling (resulting from *PIK3CA* mutations) and the pathognomonic t(12;16)(q13;p11) translocation in this subtype.

In addition to sequencing, we characterized the spectrum of genomic aberrations in soft tissue sarcoma with 250K single nucleotide polymorphism (SNP) arrays for somatic copy number alterations (SCNAs: n=207; [Figure 1](#F1){ref-type="fig"} and [Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}) and loss-of-heterozygosity (LOH) (n=200; [Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}) and with oligonucleotide gene expression arrays (n=149) (see Methods). The patterns of statistically significant SCNAs[@R22],[@R23] ([Figure 1](#F1){ref-type="fig"}) revealed substantial differences between subtypes with simple and complex karyotypes ([Figure 1](#F1){ref-type="fig"}). Myxoid/round-cell liposarcoma, synovial sarcoma, and GIST had relatively normal karyotypes compared to dedifferentiated and pleomorphic liposarcoma, leiomyosarcoma, and myxofibrosarcoma. In addition, only the four complex subtypes harbored significant copy-neutral LOH ([Supplementary Figure 2B and Supplementary Table 4](#SD1){ref-type="supplementary-material"}). These types exhibit varied levels of complexity: both dedifferentiated liposarcoma and leiomyosarcoma are less complex than pleomorphic liposarcoma and myxofibrosarcoma ([Figure 1](#F1){ref-type="fig"}). The latter two subtypes were strikingly similar ([Figure 1](#F1){ref-type="fig"} and [Supplementary Figure 2A](#SD1){ref-type="supplementary-material"}), indicating they might appropriately be considered a single entity in a molecular classification, as previously suggested[@R24].

Our copy number profiling revealed both focal and broad regions of recurrent amplification ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). The alteration with the highest prevalence in any subtype was chromosome 12q amplification in dedifferentiated liposarcoma (\~90%; [Figure 1](#F1){ref-type="fig"} and [Figure 4A](#F4){ref-type="fig"}). As amplification is a common mechanism of oncogenic activation, we designed an RNA interference (RNAi) screen to help identify genes in amplified regions that are necessary for cancer cell proliferation in this subtype. We performed knockdown with short hairpin RNAs (shRNA) on 385 genes ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) in three dedifferentiated liposarcoma cell lines (LPS141, DDLS8817, and FU-DDLS-1) with copy number profiles similar to those observed in primary tumors of this subtype. A total of 2,007 shRNA lentiviruses, a median of five per gene, were tested for their effects on cell proliferation after 5 days (see Methods).

Using a statistical method, RSA (see Methods, [Supplementary Note](#SD1){ref-type="supplementary-material"}, and ref. [@R25]), we identified 99 genes whose knockdown significantly decreased cell growth in at least one cell line (nominal p\<0.05; [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). For 91 of the 99 genes, two or more independent shRNAs had anti-proliferative activity, reducing the likelihood that our results are due to off-target effects. To determine whether the effect of gene knockdown on cell proliferation was specific for dedifferentiated liposarcoma, we compared our results to a pooled shRNA screen of \~9500 genes in 12 cancer cell lines of different types[@R26] which included 58 of the 99 genes whose knock-down reduced proliferation. Only one of the 58 genes, *PSMB4*, was identified as a common essential gene, for which depletion reduced cell proliferation in ≥8 of 12 cancer cell lines in the prior study[@R26].

27 of the 99 genes whose knockdown reduced proliferation were amplified in at least one of the three dedifferentiated liposarcoma cell lines used in our study ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Among these 27 genes, the most strongly overexpressed in dedifferentiated liposarcoma compared to normal fat[@R15] was *CDK4*, a cell-cycle regulator and a known oncogene[@R27]. We confirmed that sustained knockdown of *CDK4* (\>10 days) inhibited proliferation when we assayed two of the three cell lines we screened (see Methods, [Figure 4B](#F4){ref-type="fig"}). Furthermore, pharmacological inhibition of CDK4 in dedifferentiated liposarcoma cells with PD0332991, a selective CDK4/CDK6 inhibitor currently in clinical trials[@R28], induced G1 arrest in the same two cell lines ([Figure 4C](#F4){ref-type="fig"}).

For *MDM2*, another oncogene found in focal 12q amplifications, knockdown did not significantly impair proliferation in our arrayed screen in any of the three cell lines tested. Nevertheless, proliferation was impaired by subsequent knockdown lasting more than a week when we assayed two of those three cell lines ([Figure 4D](#F4){ref-type="fig"}). Interestingly, another gene whose knockdown reduced proliferation of cells in which it was amplified was *YEATS4* (*GAS41*), encoding a putative transcription factor that represses the p53 tumor suppressor network during normal cell proliferation[@R29]. *YEATS4*, frequently co-amplified with *MDM2* ([Figure 4A](#F4){ref-type="fig"}), was transcriptionally upregulated both in tumors relative to normal adipose tissue and in tumors with amplification compared to those copy-neutral for the locus ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Repeat shRNA experiments confirmed the effect of *YEATS4* knockdown seen in the arrayed screen ([Figure 4E](#F4){ref-type="fig"}), consistent with the hypothesis that *YEATS4* and *MDM2* amplification may cooperatively repress the p53 network in dedifferentiated liposarcoma, as recently suggested[@R30]. This finding may have consequences for Nutlin-based antagonism of the p53-MDM2 interaction[@R15],[@R31] in dedifferentiated liposarcomas. Our findings lend additional support for *YEATS4* serving as a likely key amplified gene in cancer, as recently suggested through a weight-of-evidence classification scheme proposed for identifying such amplified cancer genes[@R32].

This dataset provides the most comprehensive database of sarcoma genome alterations to date, revealing genes and signaling pathways not previously associated with this group of diseases. The study results are available as a community resource that might further the biological understanding of sarcomas and, eventually, shed light on additional strategies to improve patient care. Some of our findings already have potential therapeutic implications. For instance, the *PIK3CA* mutations found in MRC constitute the first report of such mutations in a mesenchymal cancer. These mutations identify a subset of tumors that might respond to treatment with PI3K inhibitors currently in clinical trials[@R33]. Our results also provide further rationale for use of CDK4 inhibitors in dedifferentiated liposarcoma and suggest the use of mTOR inhibitors in NF1-deficient sarcomas, since loss of NF1 function appears to cause mTOR pathway activation[@R34]. Finally, these data lend support for the clinical evaluation of agents targeting the p53/MDM2 interaction in dedifferentiated liposarcoma.

This work argues for the therapeutic importance of genomic alterations in sarcoma and encourages us to pursue next-generation sequencing strategies that will continue to define the landscape of genomic aberrations in these deadly diseases.
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Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturegenetics/>.
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![Nucleotide and copy number alterations in soft-tissue sarcoma subtypes\
The statistical significance of genomic aberrations for each subtype is shown. RAE q-values \[left axis; for visualization, q-values ≤ 0.05 are considered significant, corresponding false discovery rate (FDR) ≤ 5%\] and scores (right axis) for gains and amplifications (red) and losses and deletions (blue) are plotted across the genome (chromosomes indicated at bottom). Genes harboring somatic nucleotide alterations in this study are indicated in each subtype in which they were discovered ([Table 2](#T2){ref-type="table"}).](nihms212743f1){#F1}

![*NF1* alterations in karyotypically complex sarcomas\
**A.** Somatic mutations in the NF1 protein in myxofibrosarcoma and pleomorphic liposarcoma (black triangles) and the position of the RasGAP and Cral domains (dark and light green respectively) are juxtaposed to known mutations in malignant peripheral nerve sheath tumors (MPNSTs; open triangles). **B.** Transcript expression according to copy number and sequence status in myxofibrosarcoma and pleomorphic liposarcoma compared to normal adipose tissue samples (black/red and green respectively, log~2~ expression from Affymetrix array profiling data; p-value=1.94×10^−5^, ANOVA; mutated tumors are indicated). One of the two R304\* mutant tumors lacked expression data.](nihms212743f2){#F2}

![Different effect of helical and kinase domain *PIK3CA* mutations on PI3K pathway activation and survival in myxoid/round-cell liposarcoma\
**A.** Survival for patients with tumors that harbor helical-domain mutations (red) versus kinase-domain mutations (grey), and wildtype *PIK3CA* (blue). The analysis includes the 65 patients for whom outcome information was available. Patients with mutations in either the helical or the kinase domain had a shorter disease--specific survival compared to those with wildtype *PIK3CA* (p-value = 0.0363, log-rank test). The difference in disease-specific survival between patients with helical-domain mutant tumors and those with wildtype *PIK3CA* tumors was significant (p-value=0.013, log-rank test). **B.** Western blots of myxoid/round-cell liposarcoma tumor lysates comparing the phosphorylation levels of Akt, PRAS40, and S6 kinase, as well as their protein levels, in patients with wild-type *PIK3CA* or with mutations in *PIK3CA* helical or kinase domains.](nihms212743f3){#F3}

![Genes whose knockdown is anti-proliferative in dedifferentiated liposarcoma and the consequences of *CDK4, MDM2 and YEATS4* knockdown in dedifferentiated liposarcoma\
**(A)** Integrated profile of statistically significant genomic gains/amplifications as assessed by both RAE and GISTIC (combined as described in Methods; FDR, false-discovery rate) is followed by a heatmap of copy number segmentation on 12q13.2-q32.1 in 50 patient samples of dedifferentiated liposarcomas (red is amplification, blue is deletion, each row indicates one tumor sample). Below is the position of genes from our screen encoded by this region of 12q whose knockdown is anti-proliferative in dedifferentiated liposarcoma. Bold gene symbols indicate those whose amplification produced over-expression of its transcript or those over-expressed in tumor relative to normal adipose tissue. Genes in green are highlighted in panels B--C and E. Alternative genomic regions encoding genes not on 12q whose knockdown is anti-proliferative are also included. **(B)** Effect of three validated shRNAs targeting *CDK4* on the proliferation of two cell lines, LPS141 and DDLS8817, at various time points (x-axis) with negative controls (pLKO empty vector and GFP473). Below are western blots showing the effect of shRNAs on levels of CDK4 protein (as indicated). **(C)** G1 arrest induced in LPS141 and DDLS8817 cell lines by treatment with the CDK4/CDK6 inhibitor PD0332991. MDA-MB-435 (Rb-positive) and H2009 (Rb-negative) were included as sensitive and insensitive controls. Error bars are s.d. of replicate measurements. **(D--E)** As in panel (B), effect on proliferation of three shRNAs targeting MDM2 (panel D) and YEATS4 (panel E) (negative controls: pLKO empty vector and scrambled shRNA) where each targeting shRNA resulted in reduced protein levels (at bottom). Error bars are propagated error from the ratio of mean and s.d. of measurements/replicates to time 0.](nihms212743f4){#F4}

###### 

Summary of clinical and pathologic information for 207 soft-tissue sarcoma patients

  Characteristic                                                       Value
  -------------------------------------------------------------------- ---------------
  No. of patients                                                      207
  Age \[mean±SD (range)\]                                              56±16 (7--84)
  Gender (%) [†](#TFN2){ref-type="table-fn"}                           
    Female                                                             102 (50.2)
    Male                                                               101 (49.8)
  Tumor size [§](#TFN2){ref-type="table-fn"}                           
    0--5 cm                                                            35 (17.4)
    5--10 cm                                                           65 (32.3)
    10--15 cm                                                          43 (21.4)
    \>15 cm                                                            58 (28.9)
  Primary site (%) [†](#TFN2){ref-type="table-fn"}                     
    Retro-intrabdominal                                                60 (29.6)
    Visceral                                                           
      Gastrointestinal                                                 23 (11.3)
      Genitourinary                                                    4 (2)
      Gynecological                                                    1 (0.5)
    Thoracic                                                           12 (5.9)
    Extremity                                                          93 (45.8)
    Trunk                                                              8 (3.9)
    Head and Neck                                                      2 (1)
  Stage at time of sample procurment [‡](#TFN2){ref-type="table-fn"}   
    Primary                                                            139 (68.8)
    Local recurrence                                                   29 (14.4)
    Distant recurrence                                                 34 (16.8)
  Histology                                                            
    Dedifferentiated liposarcoma                                       50 (24.2)
    Myxoid/round cell liposarcoma                                      21 (10.1)
    Pleomorphic liposarcoma                                            24 (11.6)
    Leiomyosarcoma                                                     27 (13)
    Gastrointestinal stromal tumor                                     
      Epithelioid                                                      4 (1.9)
      Spindle                                                          11 (5.3)
      Mixed or unspecified                                             7 (3.4)
    Myxofibrosarcoma                                                   
      Myxofibrosarcoma                                                 35 (16.9)
      Pleomorphic MFH                                                  3 (1.5)
    Synovial sarcoma [‖](#TFN1){ref-type="table-fn"}                   
      Monophasic                                                       19 (9.2)
      Biphasic                                                         4 (1.9)
  Median follow-up (months)                                            35.65
  Time to distant recurrence (months)                                  15.7
  Co-morbidities                                                       57 (27.5)

One synovial sarcoma not specified

Data available for §201, †203, and ‡202 patients respectively

###### 

Mutations identified in soft tissue sarcoma

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       No. of\                               Subtype       Tumor ID   Cases\                               mRNA                                          Protein
             mut.[a](#TFN4){ref-type="table-fn"}                            affected\                                                                          
                                                                            (%)[b](#TFN5){ref-type="table-fn"}                                                 
  ---------- ------------------------------------- ------------- ---------- ------------------------------------ --------------------------------------------- ---------------------------------------------
  *CDH1*     2                                     DDLPS         PT7DD      2                                    712A\>AG                                      N238D

                                                   GIST          PT61GT     4.5                                  1849G\>AG                                     A617T[e](#TFN7){ref-type="table-fn"}

  *CTNNB1*   2                                     DDLPS         PT18DD     2                                    122C\>CT                                      T41I[d](#TFN7){ref-type="table-fn"}

                                                   Synovial      PT195SYN   4                                    95A\>AT                                       D32V[d](#TFN7){ref-type="table-fn"}

  *EPHA1*    1                                     DDLPS         PT10DD     2                                    634G\>GA                                      A212T

  *EPHA5*    1                                     Pleomorphic   PT182PL    4.2                                  2386A\>AG                                     Y796H

  *EPHA7*    1                                     MYXF          PT106MF    2.6                                  1649C\>CT                                     S550N

  *ERBB4*    2                                     MYXF          PT130MF    2.6                                  3437A\>AT                                     D1146V

                                                   Pleomorphic   PT167PL    4.2                                  1558A\>AT                                     C520S

  *FBXW7*    2                                     DDLPS         PT38DD     2                                    338_342delTCATC\>TC                           E113fs

                                                   GIST          PT58GT     4.5                                  563G\>GT                                      C188F

  *IRS1*     1                                     GIST          PT61GT     4.5                                  3406C\>CT                                     E1136K

  *KIT*      6                                     GIST          PT57GT     23                                   1727T\>CT                                     L576P[d](#TFN7){ref-type="table-fn"}

                                                   GIST          PT63GT                                          1961T\>CT                                     V654A[d](#TFN7){ref-type="table-fn"}

                                                   GIST          PT61GT                                          1667_1674delAGTGGAAG\>AG                      Q556fs

                                                   GIST          PT60GT                                          1667_1687del[c](#TFN6){ref-type="table-fn"}   Q556_I563\>Q

                                                   GIST          PT59GT                                          1670_1675delGGAAGG                            W557_V559\>F[e](#TFN7){ref-type="table-fn"}

                                                   MRC           PT149MRC   4.8                                  2334G\>CG                                     K778N

  *LTK*      1                                     Synovial      PT190SYN   4                                    2243_2244delTT\>T                             C748fs

  *MOS*      1                                     GIST          PT61GT     4.5                                  898A\>AG                                      S300P

  *MST1R*    1                                     GIST          PT60GT     4.5                                  1229G\>AG                                     P410L

  *NF1*      7                                     MYXF          PT104MF    10.5                                 7972C\>CT                                     H2658Y

                                                   MYXF          PT104MF                                         7790C\>CT                                     S2597L

                                                   MYXF          PT127MF                                         910C\>T                                       R304\*[d](#TFN7){ref-type="table-fn"}

                                                   MYXF          PT134MF                                         910C\>T                                       R304\*[d](#TFN7){ref-type="table-fn"}

                                                   MYXF          PT102MF                                         7010T\>TG                                     L2337R

                                                   Pleomorphic   PT176PL    8.3                                  1105C\>CT                                     Q369\*[d](#TFN7){ref-type="table-fn"}

                                                   Pleomorphic   PT179PL                                         4006C\>CT                                     Q1336\*

  *NTRK1*    1                                     MYXF          PT101MF    2.6                                  2338C\>CT                                     R780W

  *PI4KA*    2                                     MYXF          PT137MF    2.6                                  4081_4088delTCTTATCT\>TCT                     1361fs

                                                   Synovial      PT203SYN   4                                    4081_4088delTCTTATCT\>TCT                     1361fs

  *PIK3CA*   6                                     MRC           PT143MRC   18                                   1633G\>AG                                     E545K[e](#TFN7){ref-type="table-fn"}

                                                   MRC           PT149MRC                                        1633G\>AG                                     E545K[e](#TFN7){ref-type="table-fn"}

                                                   MRC           PT138MRC                                        3140A\>AG                                     H1047R[e](#TFN7){ref-type="table-fn"}

                                                   MRC           PT158MRC                                        3140A\>AG                                     H1047R[e](#TFN7){ref-type="table-fn"}

                                                   Pleomorphic   PT173PL    4.2                                  1660delC                                      H554fs

                                                   Synovial      PT195SYN   4                                    1659delT                                      S553fs

  *PTEN*     2                                     MYXF          PT100MF    2.6                                  G\>CG                                         Splice site

                                                   Synovial      PT206SYN   4                                    106G\>AA                                      G36R[e](#TFN7){ref-type="table-fn"}

  *PTK2B*    1                                     Pleomorphic   PT163PL    4.2                                  G\>AG                                         Splice site

  *RB1*      1                                     Pleomorphic   PT167PL    4.2                                  1818T\>TA                                     Y606\*[e](#TFN7){ref-type="table-fn"}

  *SYK*      1                                     Pleomorphic   PT163PL    4.2                                  52G\>AA                                       G18S

  *TP53*     4                                     Pleomorphic   PT163PL    16.7                                 404C\>AA                                      C135F[e](#TFN7){ref-type="table-fn"}

                                                   Pleomorphic   PT169PL                                         464G\>AA                                      T155I

                                                   Pleomorphic   PT173PL                                         C\>CT                                         Splice site

                                                   Pleomorphic   PT164PL                                         C\>TT                                         Splice site
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DDLPS, dedifferentiated liposarcoma; GIST, gastroinstestinal stromal tumor; MRC, myxoid/round-cell liposarcoma; MYXF, myxofibrosarcoma.

Number of nonsynonymous or splice site mutations detected in either primary sequencing or extended genotyping.

Percentage of cases by subtype.

Reference allele: GTGGAAGGTTGTTGAGGAGAT.

Mutations previously identified in ^d^ soft-tissue sarcoma or in any ^e^ cancer type (COSMIC; <http://www.sanger.ac.uk/genetics/CGP/cosmic/>).
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